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We report a case with the association of well self-compensated hereditary fructose intolerance and still poorly
symptomatic Duchenne type muscular dystrophy. This case illustrates the problems of a correct diagnosis in
sub-clinical patients presenting with “cryptogenic” hypertransaminasemia.
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The epidemics of obesity at all ages is still relentless. The
cause of an incidental and persistent finding of fatty liver
and/or cryptogenic isolated mild hypertransaminasemia
(HTS) in a child may therefore tend to be more and more
undervalued and wrongly included within the spectrum
of "non alcoholic fatty liver disease" (NAFLD) [1].
Differential diagnosis with other more rare, and some-
times poorly known metabolic/genetic, conditions [2-6]
in fact is imperative to avoid these patients not to profit
of specific, possibly lifesaving, treatments [7]. An exceed-
ingly high index of suspicion is therefore required, also
because multiple causes sharing identical pathological
findings exist [8]. Here we present a case of cryptic and
well self-compensated hereditary fructose intolerance
whose identification was triggered by the accidental find-
ing of muscular hypertransaminasemia due to a still
poorly manifest Duchenne type muscular dystrophy.Case report
CS, a 3-year and 4-month old boy, was admitted to our
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reproduction in any medium, provided the orborn of non-consanguineous parents. He pronounced
his first words after the first year, and took autonomous
first steps at 24 months. Sugar, sweets and fruit refusal
was reported since early life.
The first occasional discovery of HTS at age 2 years
(Alanine aminotransferase x 5 upper normal values (unv),
Aspartate aminotransferase x 6 unv) was confirmed at 3
subsequent outpatient checks. At entry physical examin-
ation showed a well-cooperating boy, with a hypo-mimic
face. Height, weight and head circumference were normal
for age and gender. Abdomen was expanded and tense.
Liver and spleen were palpable at 5 and 1 centimeters
under the costal ridges, respectively. Liver consistency
was reduced. Mild bilateral gastrocnemius pseudohyper-
trophy was noticed. Gower sign was positive with discrete
weakness of legs antagonists, making impossible to climb
the stairs without the help of the upper limbs, and use
of supports for both the transition from sitting position
to standing, and for walking (wide base, accentuation of
the lumbar lordosis).
Bilirubin, Gamma-glutamyl transpeptidase, Albumin
and Protein serum electrophoresis, Prothrombin Time,
Partial Thromboplastin Time, Fibrinogen, Blood gases,
Lactic acid, Ammonium, Cholesterol, Triglycerides, Total
Immunoglobulins, Viral hepatitis markers (HBsAg, anti
HBc Ag, anti-HCV, anti-HAV, anti-HAV IgM), TOxoplas-
mosis, Rubella, Cytomegalovirus, and Herpes simplex andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Abnormal biochemical laboratory investigation at
entry
Test Value Normal values
Aspartate aminotransferase 245 IU/L ≤ 41 U/I
Alanine aminotransferase 224 IU/L ≤ 45 U/I
Lactic acid dehydrogenase 2,268 IU/L ≤ 882 U/I
Creatine kinase 18,369 IU/L ≤ 190 U/I
Myoglobin 1,524.9 ng/ml 0.6-6.3 ng/ml
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bodies, anti-mitochondrial antibody, anti-smooth muscle
antibodies, anti-liver-kidney microsomes-1 antibodies,
antiparietal cell antibodies, anti-endomysial antibodies
IgA, anti transaglutaminasi IgA, TSH, FT3, FT4, serum
and urinary amino acids and acylcarnitines were all nega-
tive or within normal limits for age. In addition to amino-
transferase values, also creatine kinase (CK), lactic
dehydrogenase, and myoglobin values resulted patho-
logical (Table 1).
Abdominal ultrasounds confirmed hepatomegaly
(diameter of the longitudinal middle lobe = 14 centi-
meters), with diffuse steatosis. Intra and extrahepatic
biliary tract were not dilated (Figure 1). The spleen vol-
ume was modestly increased (longitudinal and transverse
diameter of 9.5 and 5 centimeters, respectively) with a
regular echo structure.
Echocardiogram and electrocardiography did not show
any gross abnormalities.
The molecular analysis for dystrophinopathies showed
the patient be hemizygous for the macrodeletion com-
prising exons 49–50 of the dystrophin gene, compatible
with Duchenne/Becker Muscular Dystrophy. His mother
was heterozygous for the same macro-deletion.Figure 1 Abdominal ultrasound of CS with evidence of bright liver suDue to the existence of the association fatty liver and
sweet foods dislike/aversion, the molecular analysis for
the hereditary fructose intolerance (HFI), was also per-
formed. The patient eventually resulted heterozygous
for mutations pA150P and pY204X (c.612T> A), respect-
ively localized in exons 5 of the gene ALDOB. In order
to confirm that the 2 mutations were present in trans
(on two different alleles) the molecular analysis was
performed also in the two parents. This showed a com-
patible genotype with heterozygous carrier status.
At hospital discharge, due to absence of evident
muscle retraction (prevalence of hyposthenia), no need for
immediate physiatric treatments was agreed. A fructose/
sucrose/sorbitol free diet along with a list of allowed/
forbidden drugs was prescribed.
Discussion
Our case describes for the first time the association of
hereditary fructose intolerance and Duchenne muscular
dystrophy, and provides the opportunity of discussing
the difficulties in the evaluation of the finding elevated
transaminase levels in a still poorly symptomatic/
asymptomatic patient. This may represent a significant
diagnostic challenge for physicians, given the exceedingly
wide range of possible infectious, autoimmune, meta-
bolic, systemic, gastrointestinal causes of liver disease,
and also of extrahepatic origin hypertransaminasemias
[8]. A detailed evaluation of the initial history, and a
clinically oriented examination are crucial to assess the
severity, and to determine the likely etiology/etiologies
of hypertransaminasemia [8].
If hyperCKemia accompanies hypertransaminasemia
it is mandatory to exclude muscular diseases, which are
often clinically asymptomatic during the first 5–6 years
of life and are frequently recognized only after a detailedggestive of severe hepatic steatosis.
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cular dystrophy (Phenotype MIM number 310200) is
caused by mutation in the gene encoding dystrophin
(DMD; 300377) with location on Xp21.2-p21.1 [9]. In a
12-year prospective study in the Campania region of
southern Italy, Nigro et al. [10] found an incidence of
DMD of 21.7 per 100,000 male live births. In addition to
the classical muscular dystrophies (dystrophinopathies),
myocyte injury and necrosis induced by drugs or toxins,
increased exercise, and some mitochondrial, endocrine
and metabolic (e.g. storage diseases) myopathies, and
gluten enteropathy are however possible additional causes
of hyperCKemia and hypertransaminasemia, needing ac-
curate exclusion according to age and clinical scenario
[2,11,12]. The association between muscular dystrophy
and obesity related NAFLD has been recently reported as
well, and it emerges the need for a specific handling to
avoid further muscular damage consequent to excessive
caloric restriction or exercise [12]. The associated condi-
tion presented by our patient, HFI (gene locus ALDOB,
location 9q31.1, Phenotype Fructose intolerance, MIM
number 229600) [13] has an incidence of 1:20,000. In
addition to occur with a possible typical presentation
pattern of early-onset cholestasis during weaning, it may
also present later on in patients who spontaneously
follow a low fructose diet as a result of innate fructose
dislike. In these cases, medical observation may be conse-
quent to an incidental finding of hypertransaminasemia,
and/or hepatomegaly and/or bright liver at ultrasound
observation. The correct feeding history is crucial for the
diagnosis, which may be confirmed by molecular ana-
lysis of the gene mutations as in our case. The association
of these two rare diseases has never been previously
reported: the different chromosomes involved and the
parental carrier state suggest that it is a fortuitous event.
In conclusion our case emphasizes that when hyper-
transaminasemia and/or fatty liver are diagnosed one
should nonetheless be alert to the possibility of over-
looking a series of other, possibly treatable, coincidental
causes of liver damage such as celiac disease [14,15],
Wilson disease [16], autoimmune hepatitis [17], several
genetic rarer diseases [18-20] or even muscular diseases.
Prompt recognition of some of these associated condi-
tions may be crucial to avoid invasive tests [21,22], and
immediately start appropriate therapies [23,24] that
might dramatically change the natural history of the
associated hidden cause of liver disease.
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